129 related articles for article (PubMed ID: 26613889)
1. CA-125, but not galectin-3, complements CA 19-9 for discriminating ductal adenocarcinoma versus non-malignant pancreatic diseases.
Coppin L; Benomar K; Corfiotti F; Cattan S; Renaud F; Lapere C; Leteurtre E; Vantyghem MC; Truant S; Pigny P
Pancreatology; 2016; 16(1):115-20. PubMed ID: 26613889
[TBL] [Abstract][Full Text] [Related]
2. Immunocytochemistry for MUC4 and MUC16 is a useful adjunct in the diagnosis of pancreatic adenocarcinoma on fine-needle aspiration cytology.
Horn A; Chakraborty S; Dey P; Haridas D; Souchek J; Batra SK; Lele SM
Arch Pathol Lab Med; 2013 Apr; 137(4):546-51. PubMed ID: 23544943
[TBL] [Abstract][Full Text] [Related]
3. Integrative analysis of the cancer genome atlas and cancer cell lines encyclopedia large-scale genomic databases: MUC4/MUC16/MUC20 signature is associated with poor survival in human carcinomas.
Jonckheere N; Van Seuningen I
J Transl Med; 2018 Sep; 16(1):259. PubMed ID: 30236127
[TBL] [Abstract][Full Text] [Related]
4. MicroRNA-200c modulates the expression of MUC4 and MUC16 by directly targeting their coding sequences in human pancreatic cancer.
Radhakrishnan P; Mohr AM; Grandgenett PM; Steele MM; Batra SK; Hollingsworth MA
PLoS One; 2013; 8(10):e73356. PubMed ID: 24204560
[TBL] [Abstract][Full Text] [Related]
5. Pathobiological implications of MUC16 expression in pancreatic cancer.
Haridas D; Chakraborty S; Ponnusamy MP; Lakshmanan I; Rachagani S; Cruz E; Kumar S; Das S; Lele SM; Anderson JM; Wittel UA; Hollingsworth MA; Batra SK
PLoS One; 2011; 6(10):e26839. PubMed ID: 22066010
[TBL] [Abstract][Full Text] [Related]
6. Galectin-3 is a non-classic RNA binding protein that stabilizes the mucin MUC4 mRNA in the cytoplasm of cancer cells.
Coppin L; Vincent A; Frénois F; Duchêne B; Lahdaoui F; Stechly L; Renaud F; Villenet C; Van Seuningen I; Leteurtre E; Dion J; Grandjean C; Poirier F; Figeac M; Delacour D; Porchet N; Pigny P
Sci Rep; 2017 Mar; 7():43927. PubMed ID: 28262838
[TBL] [Abstract][Full Text] [Related]
7. Oncogenic KRAS Targets MUC16/CA125 in Pancreatic Ductal Adenocarcinoma.
Liang C; Qin Y; Zhang B; Ji S; Shi S; Xu W; Liu J; Xiang J; Liang D; Hu Q; Ni Q; Xu J; Yu X
Mol Cancer Res; 2017 Feb; 15(2):201-212. PubMed ID: 28108627
[TBL] [Abstract][Full Text] [Related]
8. Enhanced discrimination of malignant from benign pancreatic disease by measuring the CA 19-9 antigen on specific protein carriers.
Yue T; Maupin KA; Fallon B; Li L; Partyka K; Anderson MA; Brenner DE; Kaul K; Zeh H; Moser AJ; Simeone DM; Feng Z; Brand RE; Haab BB
PLoS One; 2011; 6(12):e29180. PubMed ID: 22220206
[TBL] [Abstract][Full Text] [Related]
9. Cancer Antigen 125 (CA125, MUC16) Protein Expression in the Diagnosis and Progression of Pancreatic Ductal Adenocarcinoma.
Jiang K; Tan E; Sayegh Z; Centeno B; Malafa M; Coppola D
Appl Immunohistochem Mol Morphol; 2017 Oct; 25(9):620-623. PubMed ID: 27093451
[TBL] [Abstract][Full Text] [Related]
10. Serum macrophage inhibitory cytokine 1 as a marker of pancreatic and other periampullary cancers.
Koopmann J; Buckhaults P; Brown DA; Zahurak ML; Sato N; Fukushima N; Sokoll LJ; Chan DW; Yeo CJ; Hruban RH; Breit SN; Kinzler KW; Vogelstein B; Goggins M
Clin Cancer Res; 2004 Apr; 10(7):2386-92. PubMed ID: 15073115
[TBL] [Abstract][Full Text] [Related]
11. Growth differentiation factor (GDF-15) concentration combined with Ca125 levels in serum is superior to commonly used cancer biomarkers in differentiation of pancreatic mass.
Hogendorf P; Durczyński A; Skulimowski A; Kumor A; Poznańska G; Strzelczyk J
Cancer Biomark; 2018 Feb; 21(3):505-511. PubMed ID: 29171983
[TBL] [Abstract][Full Text] [Related]
12. Validation of biomarkers that complement CA19.9 in detecting early pancreatic cancer.
Chan A; Prassas I; Dimitromanolakis A; Brand RE; Serra S; Diamandis EP; Blasutig IM
Clin Cancer Res; 2014 Nov; 20(22):5787-95. PubMed ID: 25239611
[TBL] [Abstract][Full Text] [Related]
13. The clinical utility of CA125/MUC16 in pancreatic cancer: A consensus of diagnostic, prognostic and predictive updates by the Chinese Study Group for Pancreatic Cancer (CSPAC).
Liu L; Xiang J; Chen R; Fu D; Hong D; Hao J; Li Y; Li J; Li S; Mou Y; Mai G; Ni Q; Peng L; Qin R; Qian H; Shao C; Sun B; Sun Y; Tao M; Tian B; Wang H; Wang J; Wang L; Wang W; Wang W; Zhang J; Zhao G; Zhou J; Yu X;
Int J Oncol; 2016 Mar; 48(3):900-7. PubMed ID: 26718269
[TBL] [Abstract][Full Text] [Related]
14. Inflammation, Tumoral Markers and Interleukin-17, -10, and -6 Profiles in Pancreatic Adenocarcinoma and Chronic Pancreatitis.
Tanţău A; Leucuţa DC; Tanţău M; Boţan E; Zaharie R; Mândruţiu A; Tomuleasa IC
Dig Dis Sci; 2021 Oct; 66(10):3427-3438. PubMed ID: 33184795
[TBL] [Abstract][Full Text] [Related]
15. The expressions and clinical significances of tissue and serum galectin-3 in pancreatic carcinoma.
Xie L; Ni WK; Chen XD; Xiao MB; Chen BY; He S; Lu CH; Li XY; Jiang F; Ni RZ
J Cancer Res Clin Oncol; 2012 Jun; 138(6):1035-43. PubMed ID: 22367363
[TBL] [Abstract][Full Text] [Related]
16. Ascites from ovarian cancer patients stimulates MUC16 mucin expression and secretion in human peritoneal mesothelial cells through an Akt-dependent pathway.
Matte I; Garde-Granger P; Bessette P; Piché A
BMC Cancer; 2019 Apr; 19(1):406. PubMed ID: 31039761
[TBL] [Abstract][Full Text] [Related]
17. DUSP28 links regulation of Mucin 5B and Mucin 16 to migration and survival of AsPC-1 human pancreatic cancer cells.
Lee J; Lee J; Yun JH; Jeong DG; Kim JH
Tumour Biol; 2016 Sep; 37(9):12193-12202. PubMed ID: 27230679
[TBL] [Abstract][Full Text] [Related]
18. Applicative Value of Serum CA19-9, CEA, CA125 and CA242 in Diagnosis and Prognosis for Patients with Pancreatic Cancer Treated by Concurrent Chemoradiotherapy.
Gu YL; Lan C; Pei H; Yang SN; Liu YF; Xiao LL
Asian Pac J Cancer Prev; 2015; 16(15):6569-73. PubMed ID: 26434876
[TBL] [Abstract][Full Text] [Related]
19. Galectin-3's Complex Interactions in Pancreatic Ductal Adenocarcinoma: From Cellular Signaling to Therapeutic Potential.
Dimitrijevic Stojanovic M; Stojanovic B; Radosavljevic I; Kovacevic V; Jovanovic I; Stojanovic BS; Prodanovic N; Stankovic V; Jocic M; Jovanovic M
Biomolecules; 2023 Oct; 13(10):. PubMed ID: 37892182
[TBL] [Abstract][Full Text] [Related]
20. Improved Pancreatic Adenocarcinoma Diagnosis in Jaundiced and Non-Jaundiced Pancreatic Adenocarcinoma Patients through the Combination of Routine Clinical Markers Associated to Pancreatic Adenocarcinoma Pathophysiology.
Ferri MJ; Saez M; Figueras J; Fort E; Sabat M; López-Ben S; de Llorens R; Aleixandre RN; Peracaula R
PLoS One; 2016; 11(1):e0147214. PubMed ID: 26808421
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
